Fusion Antibodies plc (LSE:FAB), the Belfast-based contract research organisation, reported a narrower operating loss and higher Revenue for the year to 31 March 2026 in final results published in mid-September. The company, which sits among the smaller life sciences constituents of the FTSE AIM All Share Index, also flagged challenging market conditions and a material uncertainty over going concern, noting that it expects to need further funding.
What the Company Does
Founded in 2001 as a spin-out from Queen's University Belfast and listed on AIM since December 2017, Fusion Antibodies provides pre-clinical antibody discovery, engineering and Supply services to pharmaceutical and biotechnology clients. Its offering includes antibody discovery, affinity maturation and sequence optimisation. According to company information reported in August 2026, its clients include eight of the world's ten largest pharmaceutical companies by revenue, and since 2012 it has sequenced and expressed more than 750 antibodies and completed over 250 humanisation projects.
Latest Developments
The company's final results were first released on 14 September 2026 and reissued the following day to correct the stated gross Margin to 58.3%, with no other details changed. Chief Executive Adrian Kinkaid described the year as one of important progress, highlighting improved service revenue in the second half and the commercial launch of OptiMAL, the company's proprietary antibody library platform, in December 2025.
OptiMAL was launched following validation work with the US National Cancer Institute, and Fusion said a formal screening agreement with the institute was being negotiated, although the timing remains uncertain. Intellectual property protection for the platform advanced after the year end. On 6 August 2026 the company announced acceptance of an Australian Patent covering two antibody families and the design methods for the libraries, and the results also referred to a patent grant in Japan and a notice of allowance in Canada. The DR5 therapeutic antibody programme with Queen's University Belfast is continuing.
Financial Picture
Revenue for the year rose to £2.1 million from £1.97 million, with around £250,000 arising from a one-off sale of intellectual property to Finn Therapeutics. Gross margin improved sharply to 58.3% from 22%. The operating loss narrowed to £1.13 million from a restated £1.63 million, even as R&D spending increased to £861,000, and the loss before tax was £1.149 million. Other Operating Income of £872,000 came mainly from the Future Medicines Institute grant programme.
Cash at the year end stood at £1.04 million, up from £0.36 million, helped by a fundraise of about £1.4 million before expenses completed in January 2026. The company does not pay a dividend.
Sector and index Context
Fusion operates in the antibody services segment of the drug discovery market, where Demand depends heavily on biotech funding conditions and pharmaceutical research budgets. Smaller service providers have faced a difficult backdrop as early-stage biotech companies have conserved cash. As one of the smaller healthcare names on the FTSE AIM All Share Index, Fusion's valuation is sensitive to contract wins and funding news.
Key Risks
The auditors' Going Concern assessment identified a material uncertainty, and the company has said it expects to require additional funding during the assessment period, which could result in dilution for shareholders. Management also expects challenging market conditions to weigh on performance in the first half of the 2027 financial year. Commercial uptake of OptiMAL and the timing of any National Cancer Institute agreement remain uncertain.
What to Watch Next
Investors will be watching for any fundraising announcement, progress on the National Cancer Institute screening agreement, further OptiMAL customer wins and patent grants, and the interim results for the six months to 30 September 2026, which will show whether second-half service momentum has carried into the new financial year.
_11_18_2026_09_42_19_750506.jpg)
_11_18_2026_09_43_10_583784.jpg)




Please wait processing your request...